Floatz logo

Ifosfamide

Transitional Cell Cancer of the Renal Pelvis and Ureter

Tulane University Health Sciences CenterPhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BBB
Carboplatin
Cardiff University
Phase 3BBB
VINBLASTINE
University of Southern California
Phase 3BBB
METHOTREXATE
University of Southern California
Phase 3BBB
Inno-206
University of Southern California
Phase 3BBB

View all 50 →

Same molecule, other indications

Ifosfamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →